Stockscreener 앱 받기
45.60
2.77%
-1.30
시간 외 거래:
45.60
Collegium Pharmaceutical Inc 주식(COLL)의 최신 뉴스
Is It Too Late To Consider Collegium Pharmaceutical (COLL) After A 40% One Year Gain? - simplywall.st
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference - GlobeNewswire
Does Collegium’s 2026 Revenue Guidance After Insider Sales Change The Bull Case For COLL? - simplywall.st
Eastern Bank Buys 45,508 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 - AOL.com
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? - Yahoo Finance
Q4 Earnings Estimate for COLL Issued By HC Wainwright - Defense World
Best value stocks to buy for Dec. 18 - MSN
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Collegium Pharmaceutical (NASDAQ:COLL) Stock - Defense World
Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? - Yahoo Finance
(COLL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Can Collegium Pharmaceutical Inc. stock outperform in 2025 bull marketRisk Management & Accurate Trade Setup Notifications - Улправда
Will Collegium Pharmaceutical Inc. stock benefit from commodity pricesMarket Trend Report & AI Powered Buy/Sell Recommendations - Улправда
Is It Time To Reassess Collegium Pharmaceutical (COLL) After Its Strong Five Year Share Price Run? - Yahoo Finance
How Collegium Pharmaceutical Inc. stock performs in weak economyMarket Trend Review & Free Accurate Trade Setup Notifications - Улправда
Is Collegium Pharmaceutical Inc. stock positioned for digital transformationMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
A Look At Collegium Pharmaceutical (COLL) Valuation After 2026 Guidance And Nucynta Authorized Generic Agreements - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 6.8% on Analyst Downgrade - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $56.00 by Analysts at Barclays - MarketBeat
How Good Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL), When It Comes To ROE? - 富途牛牛
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $56.00 - MarketBeat
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $55 - 富途牛牛
COLL FinancialsIncome Statement - Quiver Quantitative
What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical - Benzinga
Collegium Pharmaceutical (NASDAQ:COLL) Cut to “Hold” at Zacks Research - Defense World
Can Collegium Pharmaceutical Inc. stock sustain free cash flow growthJuly 2025 Retail & Daily Growth Stock Tips - Улправда
Collegium Provides 2026 Financial Guidance and Business Update - Sahm
How Collegium’s New $980 Million Credit Facility Could Reshape Collegium Pharmaceutical (COLL) Investors’ Risk Lens - Sahm
Collegium Pharmaceutical issues 2026 revenue guidance in line with estimates - MSN
Is Collegium Pharmaceutical Inc. stock trading at a premium valuationQuarterly Trade Summary & Consistent Return Strategy Ideas - Улправда
How Collegium Pharmaceutical Inc. (354) stock reacts to monetary easingJuly 2025 Setups & Advanced Technical Signal Analysis - Улправда
Needham Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛
Is Collegium Pharmaceutical Inc. (354) stock a top dividend aristocrat candidate2025 Big Picture & Consistent Growth Stock Picks - ulpravda.ru
Will Collegium Pharmaceutical Inc. stock benefit from infrastructure spendingMarket Risk Report & Real-Time Chart Pattern Alerts - ulpravda.ru
How geopolitical tensions affect Collegium Pharmaceutical Inc. stockEarnings Miss & AI Optimized Trading Strategy Guides - ulpravda.ru
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for Full Year 2026 - marketscreener.com
Collegium Pharmaceutical, Inc. Announces 2026 Financial Guidance - TradingView — Track All Markets
Star TribuneCollegium Provides 2026 Financial Guidance and Business Update - FinancialContent
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) - TradingView — Track All Markets
Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating - marketscreener.com
Is Collegium Pharmaceutical Inc a good long term investmentAutomated Trading Signals & Superior Growth Investment - earlytimes.in
Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 5%Here's What Happened - MarketBeat
Collegium Announces the Closing of $980 Million Syndicated Credit Facility - The Globe and Mail
Liquidity Mapping Around (COLL) Price Events - Stock Traders Daily
Collegium Pharmaceutical Closes New $980 Million Credit Facility - TipRanks
Collegium Pharmaceutical Closes $980 Million Syndicated Credit Facility - marketscreener.com
Collegium Pharmaceutical Signs Credit Agreement With Truist Bank - TradingView — Track All Markets
Exchange Traded Concepts LLC Reduces Holdings in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Pacer Advisors Inc. Sells 87,066 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
2 Reasons to Avoid COLL and 1 Stock to Buy Instead - Barchart.com
Collegium Pharmaceutical stock hits all-time high at 49.92 USD By Investing.com - Investing.com Nigeria
Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month HighStill a Buy? - MarketBeat
Collegium Pharmaceutical stock hits all-time high at 49.92 USD - Investing.com India
1.30%
1.45%
자본화:
|
볼륨(24시간):